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Molecular characterization of PCa and BPH using the angiogenic tissue markers CD31 and CD45 to 
differentiate between the two major types of prostate gland disorders is investigated. 8 clinically 
characterized biopsies were analyzed at the Histopathology Laboratory of the Ekiti State University 
Teaching Hospital; the tissue sections were processed for antigen retrieval and were labeled with anti-
CD45 and anti-CD31 to map the location of angiogenic cells and vascularization in BPH and PCa. The 
results showed that PCa biopsies expressed embryonic stem cell status of CD31+/CD45+, while BPH 
showed CD31-/CD45+. This suggests the presence of migrating blood cells (vascularization) in PCa and 
the absence of such in BPH. It also confirms the role of platelets in endothelial activation that can result 
to cell proliferation and apoptosis in the prostate gland of either BPH or PCa diagnosed patients.  
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INTRODUCTION  
 
Angiogenesis is a very important factor in the progression 
of benign tumors and malignancies. As the tumors get 
vascularized, mapping the angiogenesis markers is an 
important tool in detection of prostate benign neoplasm 
progression and malignancy (Ting et al., 2013). Specific 
protein targeting and labeling are important for this 
detection. The cluster of differentiations- CD31 and CD45 
were selected as the angiogenic tumor markers for PCa 
as they are important parameters in the determination of 
micro vessel density within the prostate gland (Li et al., 
2013).  CD31 (PECAM 1) is a platelet endothelial factor 
responsible for cell-to-cell adhesion and plays important 
(Cooper et al., 2002). CD31 can be localized on a wide 
variety of cells including T-lymphocytes. Of importance is 
 
 
its presence in the endothelial cells and intercellular 
junctions; this protein functions within a larger family of 
immunoglobin (Ig’s) involved in angiogenesis.  
It is also expressed in certain types of tumors 
especially in the glandular tissue of the prostate 
(Maeshima et al., 2001). Immunodetection of CD31 can 
help determine the index of vascularization as in PCa and 
BPH progression in otherwise what is called tumor 
angiogenesis or tissue angiogenesis which may be roles 
in removing aged neutrophils from the body. It is also 
important in the activation of alpha intergrin receptors 
required to hold leukocytes to the endothelium caused by 
inflammation and other fibrous tissue changes within 
glandular tissue (Gravina et al., 2013). This is also
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important in the demonstration of prostatic angiomas and 
angiosacromas (Jin et al., 2013; Tafani et al., 2011). 
CD45 is a protein tyrosine phosphate (PTP) located in 
hematopetic cells; the enzymes initiates dephosphoryla-
tion of phosphotyrosine residue and are characterized by 
homologous cyclic domains (Carvalho et al., 2013). The 
CD45 has several isoform peculiar to specific cell types; 
CD45 is a protein expressed in mature lymphocytes that 
are activated as a form of response to apoptosis; 
apoptosis not programmed cell death, but physiological 
cell death in this context (Brennen et al., 2013).  This 
study evaluates prostatic cellular disorders, (BPH and 
PCa), where CD31 is mapped against CD45 to determine 
the angiogenesis index in PCa and BPH.  
 
 
MATERIALS AND METHODS 
 
Tissue processing 
 
BPH and PCa samples (biopsies) were obtained from patients 
clinically diagnosed and histologically confirmed to have the 
condition(s) following ethical guidelines approved by the Ekiti State 
University Teaching Hospital, Ado-Ekiti. The biopsies were fixed in 
formolcalcium (4BPH and 4Pca) and processed histologically to 
obtain paraffin wax embedded sections at the Pathology Laboratory 
of Ekiti State University Teaching Hospital, Ado-Ekiti. 
 
 
Histology and immunohistochemistry 
 
Tissue sections were processed for routine hematoxylin and eosin 
following the methods of Zhang et al. (2012) to demonstrate the 
general morphology of the tissues and vessels in the tissue (small 
arteries). 
 
 
CD31/PECAM 1 
 
The following proteins were labeled in the BPH and PCa tissue 
biopsies; CD31 in the glandular tissue of the prostate, CD31 in the 
muscular part of the prostrate and CD31 in the endothelium of 
blood vessels [anti Human-CD31 monoclonal diluted in Tris buffer 
saline (TBS) 1:500].  
 
 
Lymphocytic marker (CD45+) 
 
This was demonstrated in the overall prostate tissue (glandular and 
muscular part) as an indirect measure of lymphocytic cell response 
at the onset of tumorgenesis (if any; progression of physiological 
cell death). [CD45 Anti-human monoclonal diluted in PBS at 1:100] 
 
 
Procedure 
 
The paraffin wax embedded sections were mounted on a glass 
slide in preparation for antigen retrieval where the slides were 
immersed in urea overnight and then placed in a microwave for 45 
min to re-activate the antigens and proteins in the tissue sections. 
Primary antibody treatment involved treating the sections with 
biotinylated goat serum for one hour following which the sections 
were transferred to 1% bovine serum albumin (BSA) to block non-
specific protein reactions. Secondary treatment involved the use of 
diluted anti-CD31 and anti-CD45 on the pre-treated sections for 1 h.  
 
 
 
 
The immunopositive reactions were developed using a polymer 3’3’ 
diaminobenzidine tetrachloride (DAB) with colour intensification 
involving the use of mathenamine silver kit. The sections were 
counterstained in coomasie-G250 (brilliant blue) and treated in 1% 
acid alcohol (freshly prepared). 
 
 
Transformation 
 
Mathenamine silver intensification is used on the immunopero-
xidase preparation after the peroxidase/H202/DAB reaction has 
been carried out to give a brown deposit. The sections were then 
counterstained in Hematoxylin. The counterstained sections were 
washed in running tap water, thoroughly rinsed in distilled water, 
and placed in preheated methenamine silver solution at 60°C for 5 
min.  Although it could be occasionally longer if the intensification 
had been carried out at room temperature. In this study, to further 
increase the clarity, hematoxylin was removed from counterstained 
nuclei with 1% acid alcohol before the silver intensification was 
carried out. The composition of the stock solution was 0.125% silver 
nitrate in 1.5% hexamine. The solution was stored at 4
o
C. Prior to 
use, 2 ml of 5% tetra borate was added to 50 ml of the stock silver 
solution giving a pH of 8.0, which was then filtered into a coupling 
jar and protected from sunlight.  
 
 
RESULTS AND DISCUSSION 
 
The study involves characterization of BPH and PCa 
biopsies from human prostate by staining the biopsies 
immunohistochemically using surface antigens for tumor 
angiogenic cells CD31 and CD45. The nuclei were 
stained blue following hematoxylin counter stain (Figures 
1 to 3). Over the years the controversy of a possible link 
between BPH and PCa has been extensively discussed; 
researchers have described the possibility of BPH 
progressing to PCa. To clarify the essence of the 
controversy in the first instance, BPH tissue cells will later 
become tumorgenic or secondly, the presence of 
symptoms of BPH may predispose to PCa by cellular 
activation of glandular tissue (Chen et al., 2012). 
A major feature peculiar to both BPH and PCa is an 
increase in the rate of cell proliferation. The clinical 
manifestations of prostate cancer result from the effects 
of local growth of the tumor, the spread to regional lymph 
nodes via the lymphatic system, and the hematogenous 
dissemination to distant metastatic sites. Although most 
patients with early-stage prostate cancer are asympto-
matic, locally advanced disease can lead to obstructive or 
irritative voiding symptoms that result from local tumor 
growth into the urethra or bladder neck, extension into 
the trigone of the bladder or both making it difficult to 
differentiate from symptomatic BPH. However, BPH 
arises as spherical masses of epithelial and stromal 
elements from the glands lining the proximal prostatic 
urethra. The ratio of epithelium to smooth muscle in the 
prostate can vary among individuals, from 1:3 to 4:1.  
However, larger prostates may contain more androgen-
dependent epithelial elements than smaller glands, which 
contain a higher proportion of smooth muscle. In either 
case, the outcome of BPH may be urethral obstruction 
induced   mechanically   by   epithelial    overgrowth   and  
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Figure 1. Histological demonstration of the general morphology in human prostate tissue S09, S20 and S30 
for PCa while S29 and S39 represent the general morphology of BPH tissues. Cell aggregation can be 
observed in both PCa and BPH; PCa cell aggregations are located at random in glandular tissue or close to 
the ductal epithelium, while BPH forms an arranged layered mass of cells in the fibromuscular layer. 
(Magnification ×400). 
 
 
 
dynamically by prostatic smooth muscle contraction, or a 
combination of the two (Kyprianou et al., 1996). In both 
cases, increased cell population is resultant while PCa 
contains cell populations clumped to form a tumor at 
random locations along the epithelium or glandular 
tissue, resulting in nodular swellings (Figures 1 and 2). 
The BPH appears to be a more coordinated proliferative 
process where cell detachment is not observed and the 
resultant cell mass have a defined layer like appearance.  
A major difference between BPH and PCa is that hav-
ing acquired the cell mass, the cell aggregations in PCa 
becomes highly vascularized as seen in the distribution of 
CD31 (CD31+) in 3 PCa biopsies while in BPH no 
vascularization is observed (CD31-) (Figure 2).  
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Figure 2. Immunohistochemical demonstration of CD31 in human prostate tissue S09, S20, S30 
(PCa). S38 represents the control human testicular tissue. Immunopositivity was observed S30, 
S09 and S20. Although the level of expression is lower and sparse in S09, this can be accounted 
for a function of the difference in sites where the tumor cells are localized. While S09 is epithelia, 
S20 and S30 are glandular and are accessible to vascular supply compared to S09. In the BPH 
biopsies (S39,S40 and S29), CD31 immunopositivity shows vascularisation of the BPH tissue 
mass. A feature that seem to accompany cell proliferation. (Magnification ×400). 
 
 
 
This is similar to the findings of Wong and Chen (2012) 
and Chen et al. (2012).  The platelet derived factor CD45 
are activated as a form of response to apoptosis, the 
distribution of CD45 was restricted to specific tissue sites  
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Figure 3. Immunohistochemical demonstration of CD45 in human prostate tissue S09, S20, 
S30. S38 represents the control human testicular tissue. BPH tissue biopsies  S39, S29 and 
S40). Growing evidence has implicated white adipose tissue as a source of stromal 
progenitor cell recruited to the tumor microenvironment. S09 (+), S20 (+), S30 (+). In BPH 
tissues CD45 positivity was observed around the epithelium and was absent in S29 biopsy 
(Magnification ×400). 
 
 
 
within the glandular tissue but negative for the epithelium 
in PCa biopsies while in BPH, the CD45 was found both 
around the epithelium of the gland and the fibromuscular 
layer (Figure 3). CD45 thus seem  to  be  associated  with 
 massive cell proliferation (PCa/CD45+ and BPH/CD45+).  
This is in agreement with the findings of Morelli et al. 
(2013) and Jones et al. (2013). Most of the cell death 
(CD45+) observed were restricted  to  the  surface  of  the  
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Table 1. CD31 and CD45 distribution in 4BHP and 4PCa Biopsies following 
immunohistochemistry using monoclonal antibodies against Human CD31 and CD45. 
 
PCa CD31 CD45  BPH CD31 CD45 
S09 -/+ +  S39 - + 
S20 + +  S40 - + 
S30 + +  S29 - - 
S38 + +  S38 - + 
 
 
 
tumor mass in PCa or tissue mass in BPH.  It is charac-
terized by extensive proliferation and inflammation of 
fibromuscular layer cells which has also been reported to 
be an important predisposing factor to PCa (Lazar et al., 
2012). 
In this study PCa recorded CD31+/CD45+ while BPH 
showed CD31-/CD45+ (Table 1). This result may be 
useful in predicting the management of carcinoma-in-situ 
as CD31+/CD45+ may suggest progression to PCa. 
These outcomes may also indicate infiltration of tissue 
sites by macrophages like eosinophils. There is also a 
possibility of having the presence of tumor cells from 
more than one source that is lymphomas and adeno-
carcinomas. The CD45+ elevated levels in PCa and BPH 
show activation and aggregation of platelets and 
according to the studies of Jin et al. (2013), it is a 
predisposing factor to recurrence of the tumor. 
 Combined immunodetection of CD31/CD45 also maps 
the distribution of stimulating proliferating cell popula-
tions. Studies on muscles showed that CD31+/CD45- 
characterized cells constitute about 5 to 6% of cell 
population in the muscles  while CD31-/CD45+ 
represents the status of 90% of the muscle cells (Figure 3 
and Table 1). As a form of response to inflammation, it is 
possible that CD31+/CD45+ cell population were 
recruited from elsewhere (Taffani et al., 2011). Tissue 
sites where CD31+/CD45+ have been identified includes 
embryonic prostate tissue containing stem cells 
programmed to form both glandular and muscle tissue of 
the prostate gland and this is also an evidence of re-
expression of embryonic proteins in PCa cells. While the 
CD31-/CD45+ are characteristic of muscles (90%), it 
confirms the immune mapping in BPH where the status 
was CD31-/CD45 (Table 1).  CD45 is also peculiar to 
cells that are capable of active proliferation such as 
epithelial cells which most of the time undergo exfoliative 
cytology as part of the routine of the tissue where these 
cells are localized (Mackern Oberti et al., 2011).  
Previous studies already established that CD31 is 
characteristic of angiogenic cells originating from the 
bone marrow and such CD31 cells will under defined 
conditions give rise to endothelial cells and as such it is 
important to identify cells with increased angiogenic 
activity (Poveda et al., 2011; Blann et al., 2011).  The 
CD31/CD45 immuno-mapping can also be used as a 
distinguishing factor for blood cell cancer proper or tumor 
cells that move within the blood cells (Wong et al., 2012). 
The role of endothelial cells mapped with CD31 is 
important in determining the rate of progression of BPH 
especially those linked with inflammation (Ribeiro et al., 
2012). Studies on other endothelial factors like VCAM-1 
suggests active chemical interaction in blood vessels 
(endothelium) to recruit lymphocytic cell lines into the 
area and induce apoptosis by physiological cell death in 
the BPH tissue mass or PCa cells (Lawson et al., 2007). 
In conclusion, the relative distribution of CD31/CD45 is 
an important molecular marker in determining angioge-
nesis in PCa progression and also a major tool in 
distinguishing PCa from BPH.   
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PCa; (Prostate Cancer), BPH; (Benign Prostatic 
Hyperplasia), LUTS; (Lower Urinary Tract Symptoms), 
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